More and more bacterial pathogens are developing resistance. There is an increasing risk that common drugs will no longer be effective against infectious diseases. That is why scientists around the ...

More and more bacterial pathogens are developing resistance. There is an increasing risk that common drugs will no longer be effective against infectious diseases. That is why scientists around the ...

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) in collaboration with researchers from Florida International University’s Department of Physics and ...

As more and more pathogenic bacteria gain resistance to commonly used antibiotics, the search for new, effective, and safe antibiotics has become vital. According to The Lancet, almost 5 million ...

There is a compelling need to produce new antibiotics that hamper severe opportunistic infections, especially in immunocompromised individuals, such as those caused by gram-negative Pseudomonas ...

Bacteria have an immune system that protects them against viruses known as bacteriophages. A research team from the Universities of Tübingen and Würzburg has now shown how this immune system enhances ...

The intravenous formulation of fosfomycin has a novel mechanism of action an no known cross-resistance to other antibiotic classes.

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in ...

TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases, today reports favorable findings ...

Despite determined efforts by countries and health care professionals, Europe is not on track to meet four of the five AMR ...